Equity Overview
Price & Market Data
Price: $0.45
Daily Change: -$0.01 / 2.22%
Range: $0.43 - $0.474
Market Cap: $11,779,335
Volume: 174,425
Performance Metrics
1 Week: -10.18%
1 Month: -12.79%
3 Months: -23.73%
6 Months: -30.45%
1 Year: -87.84%
YTD: -38.36%
Company Details
Employees: 57
Sector: Health technology
Industry: Biotechnology
Country: Israel
Details
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.